RT Journal Article
SR Electronic
T1 Safety of Breastfeeding in Mothers with SARS-CoV-2 Infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.30.20033407
DO 10.1101/2020.05.30.20033407
A1 Luo, Qingqing
A1 Chen, Lan
A1 Yao, Dujuan
A1 Zhu, Jianwen
A1 Zeng, Xiangzhi
A1 Xia, Lin
A1 Wu, Min
A1 Lin, Lin
A1 Jin, Zhishan
A1 Zhang, Qingmiao
A1 Feng, Dilu
A1 Yu, Shihuan
A1 Song, Bo
A1 Zhang, Wanlin
A1 Wang, Hongbo
A1 Zhang, Yanfang
A1 Su, Zhengyuan
A1 Luo, Minhua
A1 Jiang, Xuan
A1 Chen, Hui
YR 2020
UL http://medrxiv.org/content/early/2020/06/01/2020.05.30.20033407.abstract
AB Background The outbreak of Coronavirus Disease 2019 (COVID-19) is threatening a surging number of populations worldwide, including women in breastfeeding period. Limited evidence is available concerning breastfeeding in women with COVID-19.Methods Twenty-three pregnant women and puerperae were enrolled in the study. To evaluate the effect of breastfeeding on SARS-CoV-2 transmission, the presence of SARS-CoV-2, IgG and IgM in breast milk, maternal blood and infant blood were assessed. Feeding patterns were also recorded in follow-up.Results No positive detection for SARS-CoV-2 of neonates was found. All breast milk samples were negative for the detection of SARS-CoV-2. The presence of IgM of SARS-CoV-2 in breast milk was correlated with maternal blood. The results of IgG detection for SARS-CoV-2 were negative in all breast milk samples. All the infants were in healthy condition while six of them were fed with whole or partial breast milk. Eight infants received antibody test for SARS-CoV-2 in one month after birth and the results were all negative.Conclusion Findings from this small number of cases suggest that there is currently no evidence for mother-to-child transmission via breast feeding in women with COVID-19 in the third trimester and puerperium.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the National Natural Science Foundation of China (No. 81703242) and the Fundamental Research Funds for the Central Universities (No.2020kfyXGYJ008)tAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWith the permission of the corresponding authors, clinical data can be provided after publication, without names and identifiers, but not the study protocol, statistical analysis or informed consent form. Research team will provide an email address for communication. The corresponding authors have the right to decide whether to share the data or not.